Impulse Dynamics Raises $158M to Expand CCM Heart Failure Therapy

Impulse Dynamics has raised $158 million to further develop and commercialize its cardiac contractility modulation (CCM) therapy for heart failure. The Optimizer system, approved by the FDA in 2019, delivers electrical stimuli to strengthen heart contractions, potentially improving quality of life, functional capacity, and exercise tolerance. CCM devices differ from implantable cardioverter defibrillators (ICDs), which prevent fatal arrhythmias, by focusing on enhancing heart muscle performance.

The funding follows coverage by the Centers for Medicare and Medicaid Services (CMS) under an “evidence development” policy, allowing Medicare reimbursement when CCM is used in approved clinical trials. Impulse sponsors the only CMS-approved study, aiming to enroll 4,200 patients to evaluate effects on mortality and hospitalizations.

Impulse is also developing the investigational CCM-D HF System, combining CCM and ICD technologies to provide both symptom relief and life-saving benefits in a single device. The company plans to seek approval after completing six months of follow-up in the ongoing trial.

17-12-2025